Pearl River Capital, LLC Abb Vie Inc. Transaction History

Pearl River Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$159.82 - $182.1 $6.93 Million - $7.9 Million	-43,375 Reduced 93.29%	3,120 $568,000
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $6.4 Million - $7.21 Million	46,495 New	46,495 $7.21 Million
Q2 2023 Aug 11, 2023	BUY	$132.51 - $164.9 $3.92 Million - $4.88 Million	29,576 New	29,576 $3.98 Million
Q2 2022 Aug 12, 2022	BUY	$137.62 - $174.96 $3.84 Million - $4.88 Million	27,896 New	27,896 $4.27 Million
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $1.96 Million - $2.23 Million	-18,460 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $1.94 Million - $2.16 Million	18,460 New	18,460 $2.08 Million
Q4 2020 Feb 12, 2021	SELL	$80.49 - $108.67 $2.15 Million - $2.91 Million	-26,764 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $2.3 Million - $2.7 Million	26,764 New	26,764 $2.34 Million
Q1 2019 May 02, 2019	SELL	$77.14 - $90.79 $69,426 - $81,711	-900 Closed	0 $0
Q4 2018 Feb 08, 2019	BUY	$77.85 - $96.01 $70,065 - $86,409	900 New	900 $83,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.